Description

Atenativ (antithrombin i) 500 IU antithrombus i №1 vial + solvent 10 ml

Ingredients

Active ingredient: Antithrombin i 500 IU

Dosage

Dosage: The recommended dose is determined by a healthcare provider based on individual patient factors.

Indications

Indications: Atenativ is indicated for the prevention of thromboembolic events in patients with hereditary antithrombin deficiency.

Contraindications

Contraindications: Atenativ is contraindicated in patients with known hypersensitivity to antithrombin products.

Directions

Administration: Atenativ is administered intravenously under the supervision of a healthcare professional.

Scientific Evidence

Atenativ, containing antithrombin i, has shown efficacy in preventing thromboembolic events in patients with antithrombin deficiency. Studies have demonstrated the ability of antithrombin to inhibit coagulation factors, thereby reducing the risk of blood clot formation.

Research published in the Journal of Thrombosis and Haemostasis highlighted the importance of antithrombin supplementation in reducing the incidence of thrombotic events in high-risk patient populations.

Additional Information

Antithrombin i, the active ingredient in Atenativ, acts as a natural anticoagulant in the body by inhibiting thrombin and other coagulation factors. This helps maintain the balance of the coagulation system and prevents excessive blood clot formation.

Clinical trials have shown that Atenativ is well-tolerated and effective in reducing the risk of thromboembolic events in patients with antithrombin deficiency when used as directed by healthcare professionals.